News|Articles|August 28, 2017

Circa and iFormulate Collaborate to Launch Biosolvant

Circa Group, a biotechnology company, has announced a collaboration with formulation science consultancy iFormulate to launch Cyrene, a biosolvent.

On August 16, 2017, Circa Group, a biotechnology company, announced a collaboration with formulation science consultancy iFormulate to launch Cyrene, a biosolvent. Created through the conversion of platform chemical Levoglucosenone, Cyrene is a chiral dipolar aprotic solvent and bio-based alternative to polar aprotic solvents such as N-methyl-2-pyrrolidone (NMP), dimethyl carbonate (DCM), and dimethyl formamide (DMF), which are under regulatory pressure worldwide due to their toxicity.

According to company, more than two years of testing and trialing has shown the biosolvant to be a safer alternative to traditional solvents.

Commenting on the partnership, Dr. Jeff Eaves, general manager at Circa subsidiary company Circa Sustainable Chemicals UK, said in a company press release, “The market understands there is no direct drop-in replacement for traditional, toxic solvents; therefore, process and formulation trials are crucial for developing bio-based alternatives. As Cyrene is introduced across the market, we are grateful for iFormulate’s considerable industry experience and strong reputation as expert consultants to formulators across the UK and Europe. We look forward to using their formulation knowledge to support our customers.”

Dr. David Calvert, director and co-founder of iFormulate, added, “Sustainability is a critical driver for many new formulation programs. We have followed the development of Cyrene over a number of years and are looking forward to helping the Circa team as they work with customers across a number of the formulation sectors.”

Circa specializes in converting waste biomass into advanced bio-based chemicals, with a portfolio including biosolvents, flavors, and biopolymers. iFormulate provides R&D services in formulation science and technology to companies who develop and produce formulated products across a range of sectors.

Source: Circa Group


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.